ICU
HEALTHCARESeaStar Medical Holding Corp
Live · NASDAQ · May 9, Close
What's Moving ICU Today?
No stock-specific AI insight has been generated for ICU yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$4.87
Fundamentals
Trading
ICU News
20 articles- SeaStar Medical to Report First Quarter Financial Results on May 13, 2026Yahoo Finance·May 6, 2026
- ICU: Poster Presentations at AKI & CRRT 2026 Highlight SAVE Registry Data and SCD MOAYahoo Finance·Apr 1, 2026
- SeaStar Medical Showcases New Positive Data from the QUELIMMUNE SAVE Registry and an Analysis of the Unique Immunomodulatory Mechanism of the SCD Therapy at AKI & CRRT 2026Yahoo Finance·Mar 30, 2026
- SeaStar Medical Holding Corp (ICU) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ...Yahoo Finance·Mar 26, 2026
- SeaStar Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdatesYahoo Finance·Mar 25, 2026
- SeaStar Medical to Report Fourth Quarter and Year-End 2025 Financial Results on March 25, 2026Yahoo Finance·Mar 18, 2026
- OTC Markets Hosts Virtual Investor Presentation with Eric Schlorff, CEO of SeaStar Medical, and David Bautz, PhD, Senior Analyst at Zacks SCRYahoo Finance·Mar 17, 2026
- Life Sciences Virtual Investor Forum Presentations Now Available for Online ViewingYahoo Finance·Mar 13, 2026
- Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12thYahoo Finance·Mar 10, 2026
- SeaStar Medical to Present at the Life Sciences Investor Forum on March 11thYahoo Finance·Mar 9, 2026
- SeaStar Medical Announces Completion of FDA Enrollment Requirement for SAVE Surveillance Registry Evaluating QUELIMMUNE Safety for Pediatric AKIYahoo Finance·Mar 5, 2026
- ICU: Publication Validates Real-World Clinical Impact of QUELIMMUNE™ in Pediatric AKIYahoo Finance·Feb 11, 2026
- SeaStar Medical Announces Publication in Pediatric Nephrology of Positive Real-World Experience for QUELIMMUNE™ (SCD-PED) Therapy in Pediatric Acute Kidney Injury (AKI)Yahoo Finance·Feb 9, 2026
- CEO Chat with Eric Schlorff, CEO of SeaStar Medical Holding CorporationYahoo Finance·Feb 2, 2026
- SeaStar Medical to Present at Upcoming Noble Capital Markets Emerging Growth Virtual Equity ConferenceYahoo Finance·Jan 29, 2026
- ICU: Critical Care Innovation for AKI Patients; Initiating Coverage of SeaStar Medical Holding Corp.Yahoo Finance·Jan 13, 2026
- SeaStar Medical Announces 2026 MilestonesYahoo Finance·Jan 7, 2026
- SeaStar Medical to Present at Upcoming Biotech Showcase 2026 Investor ConferenceYahoo Finance·Jan 6, 2026
- SeaStar Medical Announces 1-for-10 Reverse SplitYahoo Finance·Dec 23, 2025
- SeaStar Medical Announces FDA Approval of Reduction in Mandatory Enrollment for SAVE Surveillance Registry Evaluating QUELIMMUNE™ Safety for Pediatric AKIYahoo Finance·Dec 2, 2025
All 20 articles loaded
Price Data
52-Week Range
$4.87
Fundamentals
Trading
About SeaStar Medical Holding Corp
SeaStar Medical Holding Corporation (ICU) is a pioneering biotechnology firm dedicated to advancing therapeutics for chronic kidney disease through its proprietary technologies designed to enhance renal function and reduce the reliance on invasive procedures. Positioned within a substantial and expanding market, SeaStar addresses critical unmet medical needs while focusing on innovation and clinical excellence. With a robust research and development pipeline and strategic partnerships, the company is poised to lead in renal health advancements and accelerate the commercialization of its transformative therapies.